Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 StudyJosé M. Gatell, Nadine Ktorza, Mar Masiá et al.|Clinical Infectious Diseases|2018Cited by 48
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna Gonzalez‐Cordón, Juergen Rockstroh, Lambert Assoumou et al.|Journal of Antimicrobial Chemotherapy|2021Cited by 27
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized TrialLaura Waters, Luminita Schneider, Lambert Assoumou et al.|Clinical Infectious Diseases|2022Cited by 17
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravirAna Gonzalez‐Cordón, Juergen Rockstroh, Lambert Assoumou et al.|Journal of Antimicrobial Chemotherapy|2023Cited by 2
Influence of HLA-C environment on the spontaneous clearance of hepatitis C in European HIV-HCV co-infected individualsNolwenn Legrand, Katia Gagne, G David et al.|Unknown|2020Cited by 0